The evidence for a role of B cells in multiple sclerosis

Neurology

Volumn 78, Issue 11, 2012, Pages 823-832

  Disanto, G ^a,b   Morahan, J M ^a,b   Barnett, M H ^c,d   Giovannoni, G ^e   Ramagopalan, S V ^a,b,e  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

^e QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIGEN; CD8 ANTIGEN; MONOCLONAL ANTIBODY; OLIGOCLONAL BAND; RITUXIMAB; VITAMIN D;

B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; CD8+ T LYMPHOCYTE; CELL TYPE; CENTRAL NERVOUS SYSTEM; DISABILITY; DISEASE ACTIVITY; DISEASE COURSE; DISEASE PREDISPOSITION; DRUG EFFICACY; EPSTEIN BARR VIRUS; GENETIC RISK; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; INNATE IMMUNITY; LYMPHOCYTE PROLIFERATION; MULTIPLE SCLEROSIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PRIORITY JOURNAL; RELAPSE; REVIEW; RISK FACTOR; T LYMPHOCYTE; CD4+ T LYMPHOCYTE; DRUG EFFECT; EPSTEIN BARR VIRUS INFECTION; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; PATHOLOGY; VITAMIN D DEFICIENCY;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; B-LYMPHOCYTES; CD4-POSITIVE T-LYMPHOCYTES; DISEASE PROGRESSION; EPSTEIN-BARR VIRUS INFECTIONS; HUMANS; LYMPHOCYTE ACTIVATION; MAGNETIC RESONANCE IMAGING; MULTIPLE SCLEROSIS; OLIGOCLONAL BANDS; RISK FACTORS; VITAMIN D DEFICIENCY;

EID: 84859931287     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e318249f6f0     Document Type: Review

References (60)

1. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Engl J Med 2000;343:938-952.
2. Ramagopalan SV, Dobson R, Meier UC, Giovannoni G. Multiple sclerosis: Risk factors, prodromes, and potential causal pathways. Lancet Neurol 2010;9:727-739.
3. Lassmann H, Bruck W, Lucchinetti CF. The immunopathology of multiple sclerosis: An overview. Brain Pathol 2007;17:210-218. (Pubitemid 46466140)
4. Ramagopalan SV, Ebers GC. Multiple sclerosis: Major histocompatibility complexity and antigen presentation. Genome Med 2009;1:105.
5. Klein L, Hinterberger M, Wirnsberger G, Kyewski B. Antigen presentation in the thymus for positive selection and central tolerance induction. Nat Rev Immunol 2009;9: 833-844.
6. Kasper LH, Shoemaker J. Multiple sclerosis immunology: The healthy immune system vs the MS immune system. Neurology 2010;74(suppl 1):S2-S8.
7. Barnett MH, Prineas JW. Relapsing and remitting multiple sclerosis: Pathology of the newly forming lesion. Ann Neurol 2004;55:458-468. (Pubitemid 38391962)
8. Henderson AP, Barnett MH, Parratt JD, Prineas JW. Multiple sclerosis: Distribution of inflammatory cells in newly forming lesions. Ann Neurol 2009;66:739-753.
9. Babbe H, Roers A, Waisman A, et al. Clonal expansions of CD8(+) T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction. J Exp Med 2000; 192:393-404. (Pubitemid 30629164)
10. Gay FW, Drye TJ, Dick GW, Esiri MM. The application of multifactorial cluster analysis in the staging of plaques in early multiple sclerosis. Identification and characterization of the primary demyelinating lesion. Brain 1997;120: 1461-1483.
11. Segal BM, Constantinescu CS, Raychaudhuri A, Kim L, Fidelus-Gort R, Kasper LH. Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: A phase II, double-blind, placebo-controlled, randomised, dose-ranging study. Lancet Neurol 2008;7:796-804.
12. van Oosten BW, Lai M, Hodgkinson S, et al. Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: Results of a randomized, double-blind, placebo-controlled, MR-monitored phase II trial Neurology 1997;49:351-357.
13. Brok HP, van Meurs M, Blezer E, et al. Prevention of experimental autoimmune encephalomyelitis in common marmosets using an anti-IL-12p40 monoclonal antibody. J Immunol 2002;169:6554-6563. (Pubitemid 36903508)
14. Waldor MK, Sriram S, Hardy R, et al. Reversal of experimental allergic encephalomyelitis with monoclonal antibody to a T-cell subset marker. Science 1985;227: 415-417. (Pubitemid 15153498)
15. Handel AE, Lincoln MR, Ramagopalan SV. Of mice and men: Experimental autoimmune encephalitis and multiple sclerosis. Eur J Clin Invest Epub 2011.
16. Freedman MS, Thompson EJ, Deisenhammer F, et al. Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis: A consensus statement. Arch Neurol 2005;62:865-870. (Pubitemid 40973448)
17. Owens GP, Ritchie AM, Burgoon MP, Williamson RA, Corboy JR, Gilden DH. Single-cell repertoire analysis demonstrates that clonal expansion is a prominent feature of the B cell response in multiple sclerosis cerebrospinal fluid. J Immunol 2003;171:2725-2733. (Pubitemid 37025586)
18. Lovato L, Willis SN, Rodig SJ, et al. Related B cell clones populate the meninges and parenchyma of patients with multiple sclerosis. Brain 2011;134:534-541.
19. Obermeier B, Lovato L, Mentele R, et al. Related B cell clones that populate the CSF and CNS of patients with multiple sclerosis produce CSF immunoglobulin. J Neuroimmunol 2011;233:245-248.
20. Prineas JW. Multiple sclerosis: Presence of lymphatic capillaries and lymphoid tissue in the brain and spinal cord. Science 1979;203:1123-1125. (Pubitemid 9148091)
21. Breij EC, Brink BP, Veerhuis R, et al. Homogeneity of active demyelinating lesions in established multiple sclerosis. Ann Neurol 2008;63:16-25. (Pubitemid 351240547)
22. Weber MS, Hemmer B, Cepok S. The role of antibodies in multiple sclerosis. Biochim Biophys Acta 2011;1812:239-245.
23. von Budingen HC, Harrer MD, Kuenzle S, Meier M, Goebels N. Clonally expanded plasma cells in the cerebrospinal fluid of MS patients produce myelin-specific antibodies. Eur J Immunol 2008;38:2014-2023.
24. Owens GP, Bennett JL, Lassmann H, et al. Antibodies produced by clonally expanded plasma cells in multiple sclerosis cerebrospinal fluid. Ann Neurol 2009;65:639-649.
25. Fisniku LK, Brex PA, Altmann DR, et al. Disability and T2 MRI lesions: A 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain 2008;131:808-817. (Pubitemid 351294716)
26. Lee-Chang C, Zephir H, Top I, et al. B-cell subsets upregulate alpha4 integrin and accumulate in the cerebrospinal fluid in clinically isolated syndrome suggestive of multiple sclerosis onset. Neurosci Lett 2011;487:273-277.
27. Masjuan J, Alvarez-Cermeno JC, Garcia-Barragan N, et al. Clinically isolated syndromes: A new oligoclonal band test accurately predicts conversion to MS. Neurology 2006;66: 576-578. (Pubitemid 43739891)
28. Tintore M, Rovira A, Rio J, et al. Do oligoclonal bands add information to MRI in first attacks of multiple sclerosis? Neurology 2008;70:1079-1083. (Pubitemid 351464763)
29. Ignacio RJ, Liliana P, Edgardo C. Oligoclonal bands and MRI in clinically isolated syndromes: Predicting conversion time to multiple sclerosis. J Neurol 2010;257:1188-1191.
30. Skov AG, Skov T, Frederiksen JL. Oligoclonal bands predict multiple sclerosis after optic neuritis: A literature survey. Mult Scler 2011;17:404-410.
31. Brettschneider J, Tumani H, Kiechle U, et al. IgG antibodies against measles, rubella, and varicella zoster virus predict conversion to multiple sclerosis in clinically isolated syndrome. PLoS One 2009;4:e7638.
32. Brettschneider J, Czerwoniak A, Senel M, et al. The chemokine CXCL13 is a prognostic marker in clinically isolated syndrome (CIS). PLoS One 2010;5:e11986.
33. Khademi M, Kockum I, Andersson ML, et al. Cerebrospinal fluid CXCL13 in multiple sclerosis: A suggestive prognostic marker for the disease course. Mult Scler 2011;17: 335-343.
34. Owens GP, Kraus H, Burgoon MP, Smith-Jensen T, Devlin ME, Gilden DH. Restricted use of VH4 germline segments in an acute multiple sclerosis brain. Ann Neurol 1998;43:236-243. (Pubitemid 28110126)
35. Owens GP, Winges KM, Ritchie AM, et al. VH4 gene segments dominate the intrathecal humoral immune response in multiple sclerosis. J Immunol 2007;179:6343-6351.
36. Bennett JL, Haubold K, Ritchie AM, et al. CSF IgG heavy-chain bias in patients at the time of a clinically isolated syndrome. J Neuroimmunol 2008;199:126-132.
37. Berger T, Rubner P, Schautzer F, et al. Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. N Engl J Med 2003;349: 139-145. (Pubitemid 36818783)
38. Kuhle J, Pohl C, Mehling M, et al. Lack of association between antimyelin antibodies and progression to multiple sclerosis. N Engl J Med 2007;356:371-378. (Pubitemid 46148779)
39. Sellebjerg F, Bornsen L, Khademi M, et al. Increased cerebrospinal fluid concentrations of the chemokine CXCL13 in active MS. Neurology 2009;73:2003-2010.
40. Kalinowska-Lyszczarz A, Szczucinski A, Pawlak MA, Losy J. Clinical study on CXCL13, CCL17, CCL20 and IL-17 as immune cell migration navigators in relapsing-remitting multiple sclerosis patients J Neurol Sci 2011;300:81-85.
41. Festa ED, Hankiewicz K, Kim S, et al. Serum levels of CXCL13 are elevated in active multiple sclerosis. Mult Scler 2009;15:1271-1279.
42. Kuenz B, Lutterotti A, Ehling R, et al. Cerebrospinal fluid B cells correlate with early brain inflammation in multiple sclerosis. PLoS One 2008;3:e2559.
43. Joseph FG, Hirst CL, Pickersgill TP, Ben-Shlomo Y, Robertson NP, Scolding NJ. CSF oligoclonal band status informs prognosis in multiple sclerosis: A case control study of 100 patients. J Neurol Neurosurg Psychiatry 2009;80: 292-296.
44. Imrell K, Greiner E, Hillert J, Masterman T. HLADRB115 and cerebrospinal-fluid-specific oligoclonal immunoglobulin G bands lower age at attainment of important disease milestones in multiple sclerosis. J Neuroimmunol 2009;210:128-130.
45. Serafini B, Rosicarelli B, Magliozzi R, Stigliano E, Aloisi F. Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol 2004;14:164-174. (Pubitemid 38656388)
46. Magliozzi R, Howell O, Vora A, et al. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain 2007;130:1089-1104. (Pubitemid 47355604)
47. Howell OW, Reeves CA, Nicholas R, et al. Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis. Brain Epub 2011.
48. Magliozzi R, Howell OW, Reeves C, et al. A Gradient of neuronal loss and meningeal inflammation in multiple sclerosis. Ann Neurol 2010;68:477-493.
49. Dempfle A, Scherag A, Hein R, Beckmann L, Chang- Claude J, Schafer H. Gene-environment interactions for complex traits: Definitions, methodological requirements and challenges. Eur J Hum Genet 2008;16:1164-1172.
50. Imrell K, Landtblom AM, Hillert J, Masterman T. Multiple sclerosis with and without CSF bands: Clinically indistinguishable but immunogenetically distinct. Neurology 2006;67:1062-1064. (Pubitemid 44454606)
51. Romero-Pinel L, Martinez-Yelamos S, Bau L, et al. Association of HLA-DRB1. 15 allele and CSF oligoclonal bands in a Spanish multiple sclerosis cohort. Eur J Neurol 2011.
52. Wu JS, Qiu W, Castley A, et al. Presence of CSF oligoclonal bands (OCB) is associated with the HLA-DRB1 genotype in a West Australian multiple sclerosis cohort. J Neurol Sci 2010;288:63-67.
53. Zeman AZ, Kidd D, McLean BN, et al. A study of oligoclonal band negative multiple sclerosis. J Neurol Neurosurg Psychiatry 1996;60:27-30. (Pubitemid 26013190)
54. Shimoda M, Li T, Pihkala JP, Koni PA. Role of MHC class II on memory B cells in post-germinal center B cell homeostasis and memory response. J Immunol 2006;176: 2122-2133. (Pubitemid 43201659)
55. ANZgene. Genome-wide association study identifies new multiple sclerosis susceptibility loci on chromosomes 12 and 20. Nat Genet 2009;41:824-828.
56. De Jager PL, Jia X, Wang J, et al. Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci. Nat Genet 2009;41:776-782.
57. Sawcer S, Hellenthal G, Pirinen M, et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 2011;476:214-219.
58. Graham JP, Arcipowski KM, Bishop GA. Differential B-lymphocyte regulation by CD40 and its viral mimic, latent membrane protein 1. Immunol Rev 2010;237:226-248.
59. Krumbholz M, Theil D, Cepok S, et al. Chemokines in multiple sclerosis: CXCL12 and CXCL13 up-regulation is differentially linked to CNS immune cell recruitment. Brain 2006;129:200-211. (Pubitemid 43063771)
60. Allen CD, Ansel KM, Low C, et al. Germinal center dark and light zone organization is mediated by CXCR4 and CXCR5. Nat Immunol 2004;5:943-952. (Pubitemid 39276239)